| |
Training set
| |
|---|
| |
Low ICTOS (n = 138)
|
High ICTOS (n = 116)
|
P value
|
Low ICTOS (n = 175)
|
High ICTOS (n = 73)
|
P value
|
|---|
|
Age
| | |
0.06
|
0.49
| |
0.49
|
|
< 42 years
|
45 (32.6)
|
52 (44.8)
| |
81 (46.3)
|
38 (52.1)
| |
|
≥ 42 years
|
93 (67.4)
|
64 (55.2)
| |
94 (53.7)
|
35 (47.9)
| |
|
Sex
| | |
0.02
| | |
0.40
|
|
Male
|
109 (79.0)
|
75 (64.7)
| |
144 (82.3)
|
56 (76.7)
| |
|
Female
|
29 (21.0)
|
41 (35.3)
| |
31 (17.7)
|
17 (23.3)
| |
|
Staginga
| | |
0.04
| | |
0.80
|
|
III
|
84 (70.9)
|
55 (47.4)
| |
95 (65.7)
|
46 (73.0)
| |
|
IV
|
54 (39.1)
|
61 (52.6)
| |
60 (34.3)
|
27 (37.0)
| |
|
T stagea
| | |
0.21
| | |
0.33
|
|
T1
|
4 (2.9)
|
2 (1.7)
| |
5 (2.9)
|
1 (1.4)
| |
|
T2
|
14 (10.1)
|
7 (6.0)
| |
8 (4.6)
|
5 (6.8)
| |
|
T3
|
82 (59.4)
|
62 (53.4)
| |
114 (65.1)
|
40 (54.8)
| |
|
T4
|
38 (27.5)
|
45 (38.8)
| |
48 (27.4)
|
27 (37.0)
| |
|
N stagea
| | |
0.48
|
0.08
| |
0.08
|
|
N1
|
66 (47.8)
|
47 (40.5)
| |
98 (56.0)
|
36 (49.3)
| |
|
N2
|
50 (36.2)
|
46 (39.7)
| |
62 (35.4)
|
35 (47.9)
| |
|
N3
|
22 (15.9)
|
23 (19.8)
| |
15 (8.6)
|
2 (2.7)
| |
|
Cervical nodal necrosis
| | |
0.90
| | |
0.32
|
|
No
|
99 (71.7)
|
85 (73.3)
| |
114 (65.1)
|
53 (72.6)
| |
|
Yes
|
39 (28.3)
|
31 (26.7)
| |
61 (34.9)
|
20 (27.4)
| |
|
Primary tumor volume
|
< 0.001
| |
< 0.001
|
0.56
| |
0.56
|
|
< 34 ml
|
97 (70.3)
|
53 (45.7)
| |
88 (50.3)
|
33 (45.2)
| |
|
≥ 34 ml
|
41 (29.7)
|
63 (54.3)
| |
87 (49.7)
|
40 (54.8)
| |
|
Pretreatment pEBV DNA level
| | |
0.17
| | |
0.08
|
|
< 2000 copy/ml
|
75 (54.3)
|
52 (44.8)
| |
60 (45.7)
|
24 (32.9)
| |
|
≥ 2000 copy/ml
|
63 (45.7)
|
64 (55.2)
| |
95 (54.3)
|
49 (67.1)
| |
|
Chemoradiotherapy regimen
| | |
0.22
| | |
0.64
|
|
ICT+CCRT
|
62 (44.9)
|
62 (53.4)
| |
86 (49.1)
|
39 (53.4)
| |
|
CCRT
|
76 (55.1)
|
54 (46.6)
| |
89 (50.9)
|
34 (46.6)
| |
- ICTOS Induction Chemotherapy Outcomes Score, pEBV DNA plasma Epstein–Barr Virus DNA, CCRT concurrent chemoradiotherapy, ICT, induction chemotherapy
- aStaging, T classification, and N classification were based on the 7th edition of the American Joint Committee on Cancer/International Union Against Cancer staging systems
